Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon
AUTOR(ES)
Amaral, Ivanete do Socorro Abraçado, Móia, Lizomar de Jesus Maués Pereira, Barbosa, Maria Silvia de Brito, Demachki, Samia, Araújo, Marialva Tereza Ferreira de, Soares, Manoel do Carmo
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2013-01
RESUMO
INTRODUCTION: The aim of this study was to evaluate the therapeutic response of hepatitis C in patients coinfected with human immunodeficiency virus (HIV-1). METHODS: A retrospective study of 20 patients coinfected with HIV-1/HCV who were treated in the outpatient liver clinic at the Sacred House of Mercy Foundation Hospital of Pará (Fundação Santa Casa de Misericórdia do Pará - FSCMPA) from April 2004 to June 2009. Patients were treated with 180µg PEG interferon-α2a in combination with ribavirin (1,000 to 1,250mg/day) for 48 weeks. The end point was the sustained virological response (SVR) rate (HCV RNA negative 24 weeks after completing treatment). RESULTS: The mean age of the patients was 40±9.5 years, of which 89% (n=17) were male, and the HCV genotypes were genotype 1 (55%, n=11/20), genotype 2 (10%, n=2/20) and genotype 3 (35%, n=7/20). The mean CD4+ lymphocyte count was 507.8, and the liver fibrosis stages were (METAVIR) F1 (25%), F2 (55%), F3 (10%) and F4 (10%). The early virological response (EVR) was 60%, the end-of-treatment virological response (EOTVR) was 45% and the SVR was 45%. CONCLUSIONS: The median HCV viral load was high, and in 85% of cases in which highly active antiretroviral therapy (HAART) was used, none of the patients with F3-F4 fibrosis responded to treatment. Of the twenty patients treated, 45% achieved SVR and 45% achieved EOTVR. Studies that include cases from a wider region are needed to better evaluate these findings.
Documentos Relacionados
- Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil
- Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG‐IFN α2b plus ribavirin in HIV/HCV co‐infected patients
- Avaliação da progressão da fibrose hepática de pacientes co-infectados pelo HIV/HCV em serviços de atendimento a pacientes com HIV/AIDS
- HCV virological response during treatment of chronic hepatitis C is associated with liver histological Improvement in patients with HCV/HIV co-infection
- HIV-HCV coinfection and liver cancer